BCM
CRNX icon

Burrage Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Burrage Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-294,620
Closed -$5.55M – 4
2021
Q2 		$5.55M Buy
294,620
+22,227
+8% +$391K 5.57% 7
2021
Q1 		$4.16M Buy
272,393
+48,264
+22% +$748K 3.37% 12
2020
Q4 		$3.16M Sell
224,129
-17,149
-7% -$239K 2.41% 19
2020
Q3 		$3.78M Buy
241,278
+4,884
+2% +$74.7K 2.98% 15
2020
Q2 		$4.14M Sell
236,394
-45,878
-16% -$782K 2.9% 19
2020
Q1 		$4.02M Buy
282,272
+76,546
+37% +$1.57M 3.96% 9
2019
Q4 		$5.16M Buy
+205,726
New +$3.92M 3.46% 12

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Burrage Capital Management's CRNX Position: Q3 2021 in Review

Burrage Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2021, closing a stake of 294,620 shares — an estimated $5.55M sold.

Burrage Capital Management first reported a position in CRNX in Q4 2019 and held it in 7 quarters. The position peaked at $5.55M in Q2 2021. 94 funds tracked by Wall St. Rank hold CRNX as of Q3 2021.

  • Burrage Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Burrage Capital Management sold 294,620 Crinetics Pharmaceuticals shares in Q3 2021, an estimated $5.55M.
  • Burrage Capital Management first reported a position in Crinetics Pharmaceuticals in Q4 2019 and held it in 7 quarters.
  • Burrage Capital Management's Crinetics Pharmaceuticals position peaked at $5.55M in Q2 2021.
  • 94 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2021.

Based on Burrage Capital Management's 13F filing for Q3 2021.